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The damaging processes leading to a poor outcome after 
cardiac arrest start at the onset of ischemia and continues 
during the reperfusion phase. Intensive care treatment 
in resuscitated patients relies on organ support restor-
ing normal physiology with attention to brain protection. 
Drugs have not proven beneficial in randomised trials. To 
date induced hypothermia, or targeted temperature man-
agement (TTM), is the only specific intervention imple-
mented in clinical practice. Nevertheless, its final role 
and configuration are still under debate and are currently 
being investigated.
Easily modifiable clinical physiological and metabolic 
parameters could be ideal treatment candidates to possi-
bly attenuate brain damage. In a pilot trial, strict glucose 
control was tested versus standard care with no signifi-
cant difference in the outcome, and the concept has not 
been further challenged [1]. In recent years three pos-
sible physiological candidates have been investigated in 
several observational cohorts indicating better outcome 
with higher mean arterial pressure (MAP), moderately 
elevated partial pressure of oxygen  (PaO2) and mildly 
elevated partial pressure of carbon dioxide  (PaCO2) 
[2–4]. Other reports have indicated worse outcome with 
increasing doses of vasopressors, hypotension, hypocap-
nia, severe hypercapnia and severe hyperoxia [5–7]. 
Also, completely neutral reports have been published 
[8]. A pilot trial of mild hypercapnia versus normocap-
nia (standard care) suggested better outcome and lower 
levels of biomarkers of brain damage with mildly elevated 
carbon dioxide levels [9]. The well-known limitations 
of observational inferences have called for randomised 
trials.
In this issue of Intensive Care Medicine, a Finnish/
Danish group has, in two publications, reported an ele-
gant 2 × 3 factorial multicentre pilot trial in 123 coma-
tose cardiac arrest patients—the COMACARE trial. 
The patients were randomised to one of eight groups 
with either high or low normal MAP, high or low nor-
mal  PaCO2 and normal or moderately elevated  PaO2. 
Being a pilot trial feasibility was an important outcome 
and the authors demonstrated clear and distinct separa-
tion between the groups for MAP,  PaO2 and  PaCO2. The 
primary effect outcome was serum level of neuron spe-
cific enolase (NSE) at 48 h after the arrest, a time point 
where this prognostic biomarker of brain damage sepa-
rates good from poor outcome. Interestingly there were 
no detectable differences in 48-h NSE for any of the three 
interventions, and secondary outcomes such as NSE over 
time, the biomarker S100B, cardiac troponin, global elec-
troencephalographic pattern, survival and functional out-
come at 6 months were also neutral. The overall outcome 
was strikingly good for a cardiac arrest cohort and it is 
worth emphasizing that the patient group was positively 
selected in terms of age, initial rhythm and a presumed 
cardiac cause of the arrest. The single statistically signifi-
cant finding was higher cerebral oxygen saturation, up to 
approximately 10% absolute difference, with higher levels 
for high normal  PaO2 and  PaCO2 and with the figures 
suggesting more difference for  PaCO2 than  PaO2. Vaso-
dilation due to elevated  PaCO2 and increased cerebral 
blood flow (CBF) may thus be more powerful in terms 
of increasing oxygen delivery with the chosen interven-
tion targets. In this trial CBF was, however, not measured 
and its correlation to regional cerebral saturation is not 
fully elucidated. Since oxygen content typically increases 
marginally between 10 and 25  kPa and the content of 
oxygen in blood is more influential on CBF than  PaO2, it 
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is reasonable not to expect a tremendous effect on CBF 
or cerebral saturation with the oxygen intervention in 
this trial [10]. Importantly the changes in cerebral satu-
ration were not translated to any other outcome differ-
ences. Higher MAP did not influence cerebral saturation 
(or any other outcome), perhaps because of the adequate 
cerebral perfusion pressure obtained already at the low 
normal level of MAP. In contrast, a recent randomised 
trial, presented at American Heart Association 2018, 
did report that a higher target MAP (85–100  mmHg) 
improved cerebral perfusion and oxygenation [11]. Signs 
of anoxic brain damage on magnetic resonance imaging 
and functional outcome were, however, neutral.
NSE has been used as a surrogate outcome in several 
cardiac arrest trials as it is a good discriminator of poor 
and good outcome [12]. A considerable drawback with 
NSE is the sensitivity to haemolysis due to leakage of NSE 
from red blood cells [13]. The authors report that seven 
analyses were excluded as a result of haemolysis and 
only one sample at the 48-h primary outcome. However, 
haemolysis was only analysed in one of the participating 
countries and the cut-off level for exclusion due to hae-
molysis was very high (> 500 mg free haemoglobin/L). A 
value of 300 mg/L is already considered visible haemoly-
sis, and NSE levels are heavily influenced at much lower 
degrees of haemolysis and dependent on the relationship 
between NSE and haemolysis [14]. With lower serum 
levels of NSE little haemolysis can be tolerated, while 
with higher levels more haemolysis is tolerated. With 
the modest median levels of NSE reported in this trial a 
much lower cut-off level for exclusion due to haemolysis 
should have been employed, and significant haemolysis 
was therefore likely higher than reported. The influence 
on the trial results are difficult to appreciate. Reassur-
ingly, NSE findings were in line with all other outcomes 
and the levels were not used for prognostication but for 
comparison between groups. For future trials, other bio-
markers such as protein-tau or neurofilament, not or less 
sensitive to haemolysis, may prove better surrogate out-
comes [15].
A common critique of clinical trials includes questions 
of timing and dose of the intervention. In this trial the 
interventions were introduced immediately after emer-
gency randomisation with deferred consent. In light of 
other trials in which manipulating oxygen levels in the 
ambulance was associated with problems with hypoxia 
[16], that airways are often not secured prior to hospi-
tal admission, and that the initial phase after return of 
spontaneous circulation seldom allows for fine tuning of 
haemodynamics, the 3-h median delay seems difficult to 
shorten and likely will reflect clinical practice if any of the 
interventions are implemented. The authors designed the 
trial elegantly, randomising to extremes of normal levels 
for two of the three target interventions, and thus most of 
the patients were treated within standard care. Although 
statistically different, the interventions may thus have 
been separated too little to produce a meaningful clinical 
difference. Also, the trial was indeed a pilot with a very 
optimistic predefined power calculation (50% reduction 
of NSE) and a larger trial may very well have indicated 
more robust signals. The main and important conclusion 
of the COMACARE trial must be that the targets can 
be readily obtained for all three interventions and that 
adequately powered trials may follow, in which carbon 
dioxide manipulation possibly has the most intriguing 
physiological rationale.
Author details
1 Department of Clinical Sciences Lund, Anesthesia and Intensive Care, Lund 
University, Helsingborg Hospital, Lund, Sweden. 2 Medical Intensive Care Unit, 
AP-HP, Cochin Hospital, Paris, France. 3 Paris Descartes University, Paris, France. 
4 Departments of Cardiology and Clinical Medicine, Rigshospitalet, University 
of Copenhagen, Copenhagen, Denmark. 
Open Access
This article is distributed under the terms of the Creative Commons Attribu-
tion-NonCommercial 4.0 International License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and 
reproduction in any medium, provided you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made.  
Received: 29 November 2018   Accepted: 1 December 2018
Published online: 10 December 2018
References
 1. Oksanen T, Skrifvars MB, Varpula T, Kuitunen A, Pettila V, Nurmi J, Castren 
M (2007) Strict versus moderate glucose control after resuscitation from 
ventricular fibrillation. Intensive Care Med 33:2093–2100
 2. Elmer J, Scutella M, Pullalarevu R, Wang B, Vaghasia N, Trzeciak S, Rosario-
Rivera BL, Guyette FX, Rittenberger JC, Dezfulian C, Pittsburgh Post-
Cardiac Arrest Service (PCAS) (2015) The association between hyperoxia 
and patient outcomes after cardiac arrest: analysis of a high-resolution 
database. Intensive Care Med 41:49–57
 3. Roberts BW, Kilgannon JH, Hunter BR, Puskarich MA, Shea L, Donnino 
M, Jones C, Fuller BM, Kline JA, Jones AE, Shapiro NI, Abella BS, Trzeciak 
S (2018) Association between elevated mean arterial blood pressure 
and neurologic outcome after resuscitation from cardiac arrest: results 
from a multicenter prospective cohort study. Crit Care Med.   https ://doi.
org/10.1097/CCM.00000 00000 00347 4
 4. Vaahersalo J, Bendel S, Reinikainen M, Kurola J, Tiainen M, Raj R, Pettila V, 
Varpula T, Skrifvars MB, FINNRESUSCI Study Group (2014) Arterial blood 
gas tensions after resuscitation from out-of-hospital cardiac arrest: associ-
ations with long-term neurologic outcome. Crit Care Med 42:1463–1470
 5. Bro-Jeppesen J, Annborn M, Hassager C, Wise MP, Pelosi P, Nielsen N, 
Erlinge D, Wanscher M, Friberg H, Kjaergaard J, TTM Investigators (2015) 
Hemodynamics and vasopressor support during targeted temperature 
management at 33 degrees C versus 36 degrees C after out-of-hospital 
cardiac arrest: a post hoc study of the target temperature management 
trial. Crit Care Med 43:318–327
 6. McKenzie N, Williams TA, Tohira H, Ho KM, Finn J (2017) A systematic 
review and meta-analysis of the association between arterial carbon 
dioxide tension and outcomes after cardiac arrest. Resuscitation 
111:116–126
289
 7. Roberts BW, Kilgannon JH, Hunter BR, Puskarich MA, Pierce L, Donnino M, 
Leary M, Kline JA, Jones AE, Shapiro NI, Abella BS, Trzeciak S (2018) Asso-
ciation between early hyperoxia exposure after resuscitation from cardiac 
arrest and neurological disability: prospective multicenter protocol-
directed cohort study. Circulation 137:2114–2124
 8. Ebner F, Harmon MBA, Aneman A, Cronberg T, Friberg H, Hassager C, 
Juffermans N, Kjaergaard J, Kuiper M, Mattsson N, Pelosi P, Ullen S, Unden 
J, Wise MP, Nielsen N (2018) Carbon dioxide dynamics in relation to neu-
rological outcome in resuscitated out-of-hospital cardiac arrest patients: 
an exploratory target temperature management trial substudy. Crit Care 
22:196
 9. Eastwood GM, Schneider AG, Suzuki S, Peck L, Young H, Tanaka A, 
Martensson J, Warrillow S, McGuinness S, Parke R, Gilder E, McCarthy L, 
Galt P, Taori G, Eliott S, Lamac T, Bailey M, Harley N, Barge D, Hodgson CL, 
Morganti-Kossmann MC, Pebay A, Conquest A, Archer JS, Bernard S, Stub 
D, Hart GK, Bellomo R (2016) Targeted therapeutic mild hypercapnia after 
cardiac arrest: a phase II multi-centre randomised controlled trial (the 
CCC trial). Resuscitation 104:83–90
 10. Johnston AJ, Steiner LA, Gupta AK, Menon DK (2003) Cerebral oxy-
gen vasoreactivity and cerebral tissue oxygen reactivity. Br J Anaesth 
90:774–786
 11. Ameloot K, De Deyne C, Ferdinande B, Dupont M, Palmers PJ, Petit T, 
Eertmans W, Moonen C, Belmans A, Lemmens R, Dens J, Janssens S (2017) 
Mean arterial pressure of 65 mm Hg versus 85–100 mm Hg in comatose 
survivors after cardiac arrest: rationale and study design of the Neuropro-
tect post-cardiac arrest trial. Am Heart J 191:91–98
 12. Stammet P, Collignon O, Hassager C, Wise MP, Hovdenes J, Aneman A, 
Horn J, Devaux Y, Erlinge D, Kjaergaard J, Gasche Y, Wanscher M, Cronberg 
T, Friberg H, Wetterslev J, Pellis T, Kuiper M, Gilson G, Nielsen N, TTM-Trial 
Investigators (2015) Neuron-specific enolase as a predictor of death 
or poor neurological outcome after out-of-hospital cardiac arrest and 
targeted temperature management at 33 degrees C and 36 degrees C. J 
Am Coll Cardiol 65:2104–2114
 13. Ramont L, Thoannes H, Volondat A, Chastang F, Millet MC, Maquart FX 
(2005) Effects of hemolysis and storage condition on neuron-specific 
enolase (NSE) in cerebrospinal fluid and serum: implications in clinical 
practice. Clin Chem Lab Med 43:1215–1217
 14. Petinos P, Gay S, Badrick T (2015) Variation in laboratory reporting of 
haemolysis—a need for harmonisation. Clin Biochem Rev 36:133–137
 15. Moseby-Knappe M, Mattsson N, Nielsen N, Zetterberg H, Blennow K, 
Dankiewicz J, Dragancea I, Friberg H, Lilja G, Insel PS, Rylander C, Westhall 
E, Kjaergaard J, Wise MP, Hassager C, Kuiper MA, Stammet P, Wanscher 
MCJ, Wetterslev J, Erlinge D, Horn J, Pellis T, Cronberg T (2018) Serum 
neurofilament light chain for prognosis of outcome after cardiac arrest. 
JAMA Neurol. https ://doi.org/10.1001/jaman eurol .2018.3223
 16. Young P, Bailey M, Bellomo R, Bernard S, Dicker B, Freebairn R, Henderson 
S, Mackle D, McArthur C, McGuinness S, Smith T, Swain A, Weatherall M, 
Beasley R (2014) HyperOxic Therapy OR NormOxic Therapy after out-of-
hospital cardiac arrest (HOT OR NOT): a randomised controlled feasibility 
trial. Resuscitation 85:1686–1691
